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Abstract
Embryonic stem cells (ES) can self-replicate and differentiate into all cell types including insulin-
producing, beta-like cells and could, therefore, be used to treat diabetes mellitus. To date, results
of stem cell differentiation into beta cells have been debated, largely due to difficulties in defining
the identity of a beta cell. We have recently differentiated non-human primate (rhesus) embryonic
stem (rES) cell lines into insulin producing, beta-like cells with the beta cell growth factor, Exendin-
4 and using C-peptide as a phenotype marker. Cell development was characterized at each stage
by gene and protein expression. Insulin, NKX6.1 and glucagon mRNA were expressed in stage 4
cells but not in early undifferentiated cells. We concluded that rES cells could be differentiated ex
vivo to insulin producing cells. These differentiated rES cells could be used to develop a non-human
primate model for evaluating cell therapy to treat diabetes. To facilitate the identification of beta-
like cells and to track the cells post-transplantation, we have developed a marker gene construct:
fusing the human insulin promoter (HIP) to the green fluorescent protein (GFP) gene. This
construct was transfected into stage 3 rES derived cells and subsequent GFP expression was
identified in C-peptide positive cells, thereby substantiating endogenous insulin production by rES
derived cells. Using this GFP detection system, we will enrich our population of insulin producing
rES derived cells and track these cells post-transplantation in the non-human primate model.
Review
Diabetes Mellitus (DM) is a collection of heterogeneous
disorders that result in glucose homeostasis abnormalities
and produce metabolic complications that are frequently
debilitating and life threatening. Currently, approxi-
mately 17 million Americans [1-6] are affected by DM;
and this number is expected to increase by 165% in the
USA in the next 30 years [7]. Identifying methods to treat
or cure DM, along with efforts to prevent its development,
will be a key in stemming this pandemic.
Central to the development of DM is the relative loss of
insulin production from the pancreatic beta cells. Replac-
ing these cells has been a therapeutic goal for decades and
could prevent the morbidity and mortality associated with
DM. Recently, islet transplantations were successful in
restoring normal glycemic control [8]. This success
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provides proof that replacing functional β cell mass is an
effective treatment for DM.
Although islet transplantation has shown significant
promise, it remains an unlikely therapy for patients with
DM primarily due to the lack of available human islet tis-
sue [9,10]. Furthermore, individual patients will require
repeat islet transplantations to offset the slow but progres-
sive loss of transplanted islet function [11]. Since β cells
are the only sources of insulin in the body, an unlimited
and renewable supply of β cells or islets will be needed to
successfully treat DM by transplantation [12-14].
An ideal tissue source for transplantation would be β cell
lines with glucose-mediated insulin release, that are not
immunogenic, tumorogenic or at risk of transmitting
infectious disease, and are able to replicate ex vivo without
losing their differentiation potential [15]. While such a
cell line does not yet exist, islet progenitor (adult stem
cells) or embryonic stem (ES) cells are prime candidates
[13]. Both adult and embryonic stem cells have the poten-
tial to proliferate ex vivo and differentiate into islet-like
cells [16,17]. If these techniques can be translated into the
growth and isolation of islet cells, this would provide a
source of replaceable islet tissue.
Embryonic stem cells
ES cells, present in the inner cell mass of the pre-implan-
tation embryo, are immortal and pluripotent [18]. Clonal
mouse ES cell lines differentiate into islet-like pheno-
types, ex vivo [19] and in vivo [17]. This methodology has
also been applied to human ES cells; however, the process
produces a mixed population of cells containing only
about 3% insulin positive cells [20]. Although ES cells
have the potential to differentiate into islet like cells, early
work was limited by the identification of the β cell pheno-
type using insulin immunocytochemistry. This identifica-
tion method has recently been invalidated because insulin
is a growth factor present in the conditioned media used
to differentiate and grow the cells [21]. A recent publica-
tion demonstrates that insulin in the media is pinocy-
tosed into apoptotic cells and thus, is indistinguishable to
endogenous insulin when identified by immunocyto-
chemical or radioimmuno assays. Therefore, the identifi-
cation of insulin can falsely identify apoptotic cells as
insulin producing cells [21]. Subsequent to this publica-
tion, mouse ES cells were differentiated into insulin pro-
ducing cells in media containing no additional insulin
demonstrating the capacity of ES cells to develop into
insulin-producing, β-like cells [22]. These studies high-
light the need for specific and irrefutable markers of the β
cell phenotype.
Identifying beta like cells
Gene expression can be used to identify cell lineage and is
not adversely affected by compounds in the media. In
addition to insulin production and release, lineage
restricted gene expression can also be used to identify
developing β cells [23,24]. We utilized this information to
identify β cell like phenotype development from differen-
tiating rhesus ES cells and adult monkey islet cells. Total
RNA was isolated from ES cells used in three separate dif-
ferentiation experiments and RT-PCR performed using
oligonucleotides based on the human gene sequence for
genes of the pancreatic lineage. Genes associated with
early β cell development such as NeuroD [25,26] and Nes-
tin were identified in stage two cells while PDX-1 and
insulin gene expression was detectable only after stage
two, consistent with the presence of cells with a differen-
tiated phenotype (Figure 1). Gene markers of other cell
lineages including amylase and enolase were detected in
stage four cells. This suggested that cells have undergone
some degree of differentiation into β-like cells as indi-
cated by the expression of insulin and PDX-1.
Pancreatic Gene Expression Figure 1
Pancreatic Gene Expression RT-PCR was performed on 
cells from each stage of differentiation, from 3 independent 
differentiation experiments. Genes from the pancreatic cell 
lineage were identified and compared to control samples 
from rhesus adult islets. Reverse transcriptase negative sam-
ples confirmed the absence of genomic DNA (data not 
shown).Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/42
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In addition to identifying β-cell lineage restricted genes,
C-peptide, cleaved from proinsulin during insulin
processing, can be used to identify an insulin producing,
β-like cell. This methodology circumvents the problems
associated with measuring mature insulin. Since C-pep-
tide antibodies do not cross react with mature insulin or
insulin in the growth media C-peptide is a direct measure
of endogenous insulin production [27]. We were able to
identify the production of insulin by rES cells grown in
the presence of insulin using C-peptide immunocyto-
chemistry (Figure 2). This data, along with the gene
expression data, suggests that the rES cells are differentiat-
ing into insulin producing cells. At this time, however, fur-
ther modifications to the culture conditions are needed to
enhance cell differentiation and develop islet-like struc-
tures. Development of additional methods to identify the
β cell phenotype that are sensitive and specific would
greatly enhance these differentiation protocols.
Tagging ES cells for purification and 
identification post-transplantation
One approach to identifying the β cell phenotype is to tag
insulin producing cells with a fluorescent marker. Marker
genes such as the green fluorescent protein (GFP) can be
used to purify cells populations by FACS and to track cells
following transplantation [28]. We have generated a
human insulin promoter (HIP)-GFP construct to be used
specifically for these purposes. This construct will allow
GFP expression to tag insulin producing cells and provide
a means to purify insulin producing cells from the mixed
cell population using fluorescent cell sorting (FACS).
C-peptide Expression Figure 2
C-peptide Expression Rhesus ES cells were grown in 
media containing 1 nM Exendin-4 to promote differentiation 
to β like cells. The cells were fixed, permeabilized and 
probed with anti-C-peptide antibody (1/500 dilution) from 
Linco. C-peptide staining is visualized with Texas-Red sec-
ondary anti-body and the nuclei are stained with DAPI.
GFP and C-peptide expression in HIP:GFP transfected rES  cells Figure 3
GFP and C-peptide expression in HIP:GFP trans-
fected rES cells Rhesus ES cells were grown in differentia-
tion media through stage 3 (bFGF). These cells, growing 
predominately as a monolayer on a glass coverslip, were 
transfected with the HIP:GFP construct using ExGen 500. 
Cells were allowed to differentiate in stage 3 media (bFGF) 
for 3 weeks, followed by 2 weeks in stage 4 media containing 
1 nM Exendin 4. The cells were fixed in 3.4% formaldehyde 
and permeabilized with acetone. Cells were co-stained with 
DAPI and c-peptide. GFP expression was identified using a 
specific GFP filter and C-peptide detected by Tx-Red second-
ary antibody. In this field, two cells show both GFP and C-
peptide expression (large arrows) and one cell expressing 
only C-peptide (small arrow).Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/42
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We transfected rhesus ES derived cells at stage 3, prior to
the addition of specific β cell growth factors. GFP expres-
sion was identified by fluorescent microscopy following 1
week of culture with the β cell growth factor, Exendin 4
[29-33]. Cells were co-stained for C-peptide to identify
endogenous insulin production (Figure 3). We identified
cells that co-expressed C-peptide and GFP supporting use
of the HIP-GFP construct as a method to identify insulin
producing ES derived cells. In addition to providing a
means to identify and purify insulin producing cells, tag-
ging the ES cells could allow their tracking post-transplan-
tation.
Transplantation of ES cells into diabetic animal 
models
Development of animal transplantation models will be
necessary to study the safety and efficacy of ES derived cell
transplants. For DM therapies, ES derived β cells trans-
planted into the streptozotocin induced diabetic SCID
mouse should provide elementary insights. In the past,
use of rhesus monkeys and other non-human primate
models provided critical information resulting in changes
to the islet transplant protocol [34,35]. As with islet trans-
plantation studies, the rhesus monkey has proved to be an
invaluable model for other diabetes-related studies [36-
38]. Therefore, an ideal primate model to study transplan-
tation of ES cells is the chemically induced diabetic rhesus
monkey. Tagging the ES derived cells prior to transplanta-
tion will provide an important tool in the investigation of
ES cell transplantation.
Conclusion
The high cost and rising number of affected patients
makes diabetes a major health crisis for the entire world.
Current therapeutic options, with the exception of islet
transplantation, have, at best, reduced the effects of
diabetes. Stem cells (adult or embryonic) are currently the
most promising candidates for islet cell replacement ther-
apies. Recent advances differentiating embryonic stem
cells into insulin producing cells have pointed out this
potential, as well as, the pitfalls to the current approach.
We have demonstrated insulin production from rhesus ES
cells using C-peptide as a marker, thus avoiding the pitfall
of insulin detection. In addition, we have transfected ES
cells with a HIP-GFP construct to identify insulin produc-
ing, ES derived cells. This methodology will allow us to
develop a pre-clinical model of cell transplantation in
rhesus monkeys. Such a model is critical in the evaluation
of the ES cell-based transplantation safety and efficacy.
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